Table 2.
Clinical data and most relevant acute renal lesions observed by light microscopy, immunostaining, in situ hybridization
| Patient Status | Glomeruli Tubulointerstitium Peritubular Capillaries Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Data | |||||||||||||||
| Patient ID | Ischemia | Capillary Congestion | Endothelial Cell Swelling | Acute Tubular Necrosis | Tubular vacuolization | Capillaritis | Congestion | IHC | ISH | DM | HTN | AKI stage | Proteinuria mg/g | |||
| Severity Extent | Tubules | Glomeruli Tubules | ||||||||||||||
| COVIDICU | 3 | N | Y | N | Mild | >0%–25% | N | ptc1 | Y | >10% | NA | NA | N | Y | 2 | 333 |
| 4 | Y | Y | N | Mild | >0%–25% | >0%–25% | ptc0 | Y | N | Y | Y | Y | N | N | 595 | |
| 6 | Y | Y | N | Mild | 26%–50% | N | ptc1 | Y | <1% | NA | NA | N | Y | 2 | 453 | |
| 7 | Y | N | N | Severe | >50% | >0%–25%a,b | ptc0 | Y | <1% | NA | NA | N | Y | RRT | 353 | |
| 8 | N | N | N | Severe | >50% | N | ptc2 | Y | <1% | N | Bdl | N | N | RRT | 689 | |
| 10 | N | N | N | Severe | >50% | N | ptc0 | Y | <1% | N | N | Y | Y | RRT | 317 | |
| 11 | N | Y | Y | Mild | 26%–50% | 26%–50%a,b | ptc0 | Y | <1% | Bdl | Bdl | N | N | 1 | 230 | |
| 13 | N | Y | N | Mild | >0%–25% | >0%–25% | ptc0 | Y | N | NA | NA | Y | Y | 3 | 834 | |
| 15 | N | Y | N | Moderate | >50% | >0%–25% | ptc0 | N | N | N | N | N | Y | 2 | 728 | |
| 16 | N | N | N | Mild | >50% | N | ptc0 | Y | N | NA | NA | Y | N | N | 1484 | |
| Non-ICU | 1 | Y | Y | N | Mild | >0%–25% | N | ptc0 | Y | 1%–10% | N | N | Y | N | N | NA |
| 2 | N | N | N | Mild | >0%–25% | N | ptc0 | Y | N | Y | Y | Y | Y | N | 303 | |
| 5 | N | N | N | Mild | >0%–25% | >0%–25%* | ptc0 | Y | N | N | Bdl | Y | N | N | 1104 | |
| 9 | N | Y | N | Mild | >0%–25% | >0%–25% | ptc0 | Y | 1%–10% | Bdl | Bdl | Y | Y | N | 268 | |
| 12 | Y | N | N | Mild | >0%–25% | 26%–50% | ptc0 | Y | N | NA | NA | Y | Y | 2 | 6004 | |
| 14 | N | Y | N | Mild | 26%–50% | >0%–25% | ptc0 | N | <1% | NA | NA | N | Y | 1 | 579 | |
| Control ICU | P1 | N | N | Y | Mild | 26%–50% | Na | ptc0 | N | N | N | N | 1 | 654 | ||
| R1 | Y | N | N | Severe | >50% | >50% | ptc2 | N | N | N | Y | 3 | 387 | |||
| R2 | N | N | N | Severe | >50% | Na | ptc0 | Y | N | Y | N | 2 | 2607 | |||
| R3 | N | N | N | Moderate | >50% | >0%–25%a | ptc0 | N | N | Y | Y | RRT | NA | |||
| R4 | N | N | N | Severe | >50% | 26%–50% | ptc0 | N | N | N | N | 2 | NA | |||
Capillaritis was scored according to the Banff scoring system (0, <10% cortical PTC containing leukocytes; 1, ≥10% cortical PTC containing 3–4 leukocytes; 2, ≥10% cortical PTC containing 5–10 leukocytes) (41). ID, identification number; IHC, immunohistochemistry; ISH, in situ hybridization; DM, diabetes mellitus; HTN, hypertension; COVID, coronavirus disease; ICU, intensive care unit; N, not detected; Y, detected; NA, not available; PTC, peritubular capillaries; Bdl, borderline.
a
Patients exposed to IV contrast.
b
Patients treated by calcineurin inhibitor.